Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 May 2026

Hayward Sarah, Blaiss Cassidy, Zacholski Erin Hickey, MacDonald Jennifer

Abstract excerpt

The combination of avutometinib (a rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase [RAF/MEK] inhibitor) and defactinib (a focal adhesion kinase [FAK] inhibitor) demonstrated meaningful efficacy and tolerability in recurrent KRAS-mutated low-grade serous ovarian carcinoma, as evidenced by clinically meaningful response rates and manageable adverse events. Avutometinib plus defactinib is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coumarins

Share to Cystadenocarcinoma, Serous

Share to Drug Combinations

Share to Neoplasm Recurrence, Local

Share to Pyrazines

Share to Sulfonamides

Source

Identifiers

PMID: 42000305
DOI: 10.1016/j.ijgc.2026.104635

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.PMID 42000305Read ↗

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.Semantic proximity Read ↗

Avutometinib and Defactinib: First Approval.Semantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutationSemantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaSemantic proximity Read ↗

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Semantic proximity Read ↗

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerSemantic proximity Read ↗

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.